midazolam has been researched along with bumetanide in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 4 (26.67) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andoh, T; Goto, T; Kamiya, Y; Koyama, Y; Mihara, T; Miyazaki, T; Morita, S; Uchimoto, K | 1 |
| Ala-Kurikka, T; Gailus, B; Hampel, P; Johne, M; Kaila, K; Löscher, W; Römermann, K; Theilmann, W | 1 |
| Ben-Ari, Y; Delpire, E | 1 |
| Criscione, R; Falsaperla, R; Marino, S; Pisani, F; Praticò, A; Ruggieri, M; Sortino, V | 1 |
| Johne, M; Löscher, W; Welzel, B | 1 |
2 review(s) available for midazolam and bumetanide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Efficacy of the anti-seizure medications in acute symptomatic neonatal seizures caused by stroke. A systematic review.
Topics: Anticonvulsants; Bumetanide; Epilepsy; Humans; Infant, Newborn; Infant, Newborn, Diseases; Levetiracetam; Lidocaine; Midazolam; Phenobarbital; Stroke | 2022 |
13 other study(ies) available for midazolam and bumetanide
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Bumetanide, an inhibitor of cation-chloride cotransporter isoform 1, inhibits γ-aminobutyric acidergic excitatory actions and enhances sedative actions of midazolam in neonatal rats.
Topics: Aging; Animals; Animals, Newborn; Bumetanide; CA3 Region, Hippocampal; Calcium; Calcium Signaling; Cyclic AMP Response Element-Binding Protein; Diuretics; Drug Synergism; GABA Antagonists; gamma-Aminobutyric Acid; Hypnotics and Sedatives; Midazolam; Rats; Rats, Sprague-Dawley; Reflex; Solute Carrier Family 12, Member 2; Up-Regulation | 2013 |
Phenobarbital and midazolam suppress neonatal seizures in a noninvasive rat model of birth asphyxia, whereas bumetanide is ineffective.
Topics: Animals; Animals, Newborn; Anticonvulsants; Asphyxia Neonatorum; Bumetanide; Disease Models, Animal; Female; Hypnotics and Sedatives; Male; Midazolam; Phenobarbital; Rats; Rats, Wistar; Seizures; Sodium Potassium Chloride Symporter Inhibitors; Treatment Outcome | 2021 |
Phenobarbital, midazolam, bumetanide, and neonatal seizures: The devil is in the details.
Topics: Animals; Anticonvulsants; Bumetanide; Epilepsy; Humans; Midazolam; Phenobarbital; Prohibitins; Seizures; Solute Carrier Family 12, Member 2 | 2021 |
Bumetanide potentiates the anti-seizure and disease-modifying effects of midazolam in a noninvasive rat model of term birth asphyxia.
Topics: Animals; Anticonvulsants; Asphyxia; Asphyxia Neonatorum; Bumetanide; Epilepsy; Humans; Infant, Newborn; Midazolam; Phenobarbital; Rats; Seizures; Solute Carrier Family 12, Member 2; Term Birth | 2023 |